Genelabs Announces Publication In New England Journal Of Medicine Of Clinical Trial Results With Hepatitis E Virus Vaccine

... Genelabs Technologies, Inc. (Nasdaq: GNLB) today announced publication of the results of a clinical trial with an investigational hepatitis E virus (HEV) vaccine in the March 1, 2007 issue of the New England Journal of Medicine. In an article entitled Safety and Efficacy of a Recombinant Hepatitis E Vaccine, the authors report that the investigational vaccine was found to be 95. [click link for full article] ...